Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the peripheral vasodilator drugs market right now?

The market size for peripheral vasodilator drugs has seen robust growth in the past few years. Its growth is projected to continue, increasing from $6.27 billion in 2024 to $6.67 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The expansion in the historical period can be linked to the transition towards less invasive surgical procedures, an increasing demand for minimally invasive structural heart devices, ongoing training and educational initiatives for healthcare professionals, a rise in healthcare spending, and an increasing patient preference for non-surgical or minimally invasive treatments.

How fast Is the peripheral vasodilator drugs market expected to grow, and what’s its future value?

The market for peripheral vasodilator drugs is predicted to experience significant expansion in the coming years, hitting a value of $8.44 billion by 2029, which signifies a compound annual growth rate (CAGR) of 6.1%. The upward trajectory during the prediction period can be associated with factors such as the rise in the elderly population, heightened consciousness about cardiac health, the commencement of screening protocols, beneficial compensation policies for structural heart treatments, and timely authorization for newly developed structural heart devices. The forecast period will also witness major trends like amplified collaborations, application of real-world evidence, gene therapy, preventative measures, and the introduction of value-driven healthcare services.

Get your peripheral vasodilator drugs market report here!

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

What are the leading drivers of growth in the peripheral vasodilator drugs market?

The rising incidence of cardiovascular diseases is anticipated to fuel the expansion of the peripheral vasodilator drug market in the future. Disorders impacting the heart and blood vessels, often brought about by atherosclerosis, comprise the group known as cardiovascular diseases (CVDs). These manifest as heart attacks, strokes, hypertension, and heart failure. Sedentary lifestyles, poor eating habits, aging demographic patterns, increasing obesity rates, and related medical conditions such as diabetes and hypertension primarily contribute to the rise of cardiovascular diseases. In relation to cardiovascular diseases, peripheral vasodilators enhance blood circulation, lower blood pressure, reduce the burden on the heart, and ease symptoms of diseases like peripheral arterial disease. For example, the Australian Institute of Health and Welfare, a governmental entity based in Australia, recorded a rise in physician-verified deaths due to coronary heart disease (CHD) from 14,100 in 2021 to 14,900 in 2022 in June 2024. Consequently, escalating prevalence of cardiovascular diseases is propelling the expansion of the peripheral vasodilator drug market.

What are the key segments defining the peripheral vasodilator drugs market?

The peripheral vasodilator drugs market covered in this report is segmented –

1) By Drug Type: Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types

2) By Indication: Hypertension, Angina, Heart Failure, Other Indications

3) By Application: Hospital, Retail Pharmacies, Other Applications

Subsegments:

1) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

2) By Direct-Acting Vasodilators: Hydralazine, Minoxidil, Nitroprusside

3) By Alpha-Adrenergic Blockers: Prazosin, Doxazosin, Terazosin

4) By Potassium Channel Activators: Nicorandil, Diazoxide

5) By Nitrates: Nitroglycerin, Isosorbide Dinitrate, Isosorbide Mononitrate

6) By Other Types: Phosphodiesterase Inhibitors, Endothelin Receptor Antagonists

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16508&type=smp

Who are the key players steering the development of the peripheral vasodilator drugs market?

Major companies operating in the peripheral vasodilator drugs market are Pfizer Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company, Gilead Sciences Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Merck & Co, Viatris Inc., Baxter, Teva Pharmaceutical Industries, Astellas Pharma, Daiichi Sankyo Company, Limited, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Cipla Limited, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Ipca Laboratories, Alembic Pharmaceuticals

What are the key trends shaping the future of the peripheral vasodilator drugs market?

Top-tier companies in the peripheral vasodilator drugs market are prioritizing the development of triple-drug combination therapies. This strategy aims to enhance treatment results and increase their market presence in the cardiovascular therapeutics sector. Triple-drug combination therapy is an antihypertensive fixed-dose combination (FDC) designed for patients whose blood pressure has not been sufficiently controlled with dual-drug therapies or those who cannot tolerate diuretic-based combinations. To illustrate, Ajanta Pharma Limited, a pharmaceutical corporation based in India with specialization in cardiology, launched Met XL AMT in August 2023. This innovative triple-drug combination targets hypertension management among Indian patients. It is a fixed-dose combination (FDC) of three antihypertensive components, Telmisartan, Amlodipine, and Metoprolol. These components collectively function to reduce blood pressure by dilating the blood vessels, a distinctive attribute of peripheral vasodilators. The drug is specifically sanctioned by DCGI for managing uncontrolled hypertension in conjunction with stable coronary artery disease, positioning it as the world’s first fixed-dose combination (FDC) of metoprolol succinate (extended-release) 50 mg, amlodipine 5 mg, and telmisartan 40 mg.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16508

Which regions are most influential in expanding the peripheral vasodilator drugs market?

North America was the largest region in the peripheral vasodilator drugs market in 2024. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Peripheral Artery Disease Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peripheral-artery-disease-global-market-report

Peripheral IV Catheters Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peripheral-iv-catheters-global-market-report

Peripherally Inserted Central Catheter (PICC) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peripherally-inserted-central-catheter-picc-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: